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OBJECTIVES: To carry-out a cost-effectiveness analysis (CEA) of the effect of Prega-
balin (PGB) versus usual care in refractory out-patients with Generalized Anxiety 
Disorder (GAD) treated according with usual medical practice in Mental Health 
Centers in Spain. METHODS: CEA was carried-out by means of a nested case-control 
design which used secondary data extracted at random from a 6-month cohort pro-
spective observational study (the ADAN study) conducted to ascertain cost-of-illness 
in GAD (DSM-IV criteria). Refractory subjects were those who claimed of persistent 
symptoms of anxiety and showed suboptimal response (HAM-Anxiety scale q 16) 
after a course of standard doses of any anti-anxiety drug, alone or in combination, 
for 6 months. At baseline, patients could switch to PGB (monotherapy or add-on) or 
to usual care, alone or in combination, which were considered cases and controls 
respectively. Health outcomes included quality-adjusted life years (QALYs) gain by 
EQ-5D. A 3rd-payer perspective was chosen for the CEA analysis in year 2009. Sensi-
tivity analysis was performed by bootstrapping techniques (10000 re-samples were 
obtained) in order to obtain a cost-effectiveness acceptability curve. RESULTS: A total 
of 858 refractory subjects (mean baseline HAM-A; score 25.7) were identiﬁed; 429 in 
each of the PGB and UC group. Compared with UC, PGB was associated with signiﬁ-
cant higher QALY gain after 6 months of treatment; 0.12250.0995 vs 0.10090.0938 
(p  0.001), but signiﬁcantly increased health care costs; a1,240.61,407.4 vs 
a931.4940.2 (p  0.0001). The deterministic ICER ratio was a14,287 per QALY 
gained with a re-sampling ICER of a15,804 (95 CI: 15,064–16,545). The 90% of 
re-samples fold below a25,052 threshold and 95% a a30,000. CONCLUSIONS: 
Despite the design of the primary study, this evaluation could suggest that pregabalin 
may be cost-effective in comparison with usual care in refractory out-patients with 
Generalized Anxiety Disorders managed in Mental Health Centers under usual 
medical practice in Spain.
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OBJECTIVES: Aggressive behavior in early childhood affects daily life of both, the 
children and their surroundings, resulting in serious economic implications to society. 
This study analyses the cost-effectiveness of the Incredible Years (IY) parent program, 
a manualized behavioural parent training aiming at the improvement of parenting          
skills in order to reduce child aggressive behaviour -, compared to care as usual (CAU) 
in preschoolers at risk of a chronic pattern of conduct problems. METHODS: Data 
was collected on intervention costs and for both groups at different moments in time 
(before intervention, after intervention, one- and two-year follow-up) on effects 
(observed Negative Child Behavior) and on costs due to the use of public services, 
child’s damage, travel costs and productivity losses. A cost-effectiveness study was 
conducted using different perspectives that were public authorities, parent and society. 
RESULTS: Children from the IY parent program, in comparison to CAU, had a sig-
niﬁcant larger decrease on Negative Child Behavior. An effect that was even larger if 
taking only children with severe aggressive behavior. The monetary beneﬁts per child 
were larger than the intervention costs, taking the society’s perspective and the parent’s 
perspective respectively. However, from the public authorities’ perspective, the net  
costs per child to reduce the Negative Child Behavior score by one were a106. Basic  
program (12 sessions in place of 18), social worker as trainer (psychologist in base-
line), not considering informal help resulted in better a CER compared to baseline, 
whereas costs for recruiting, parking fees and the inclusion of loss of leisure time 
would. CONCLUSIONS: Seen from the society’s perspective, the intervention is 
unambiguously dominant over CAU. Children from the IY parent program had 
a signiﬁcant larger decrease on Negative Child Behavior than those from the CAU 
condition. And from the society’s perspective the IY parent program was even 
cost-saving.
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OBJECTIVES: To assess the cost effectiveness of risperidone LAI compared with oral 
risperidone and oral olanzapine over a 1-year time period in outpatient with schizo-
phrenia who had previously suffered a relapse requiring hospitalization as south Korea 
health care system. METHODS: Published medical literature and hospital electronic 
data were used to populate a decision-analysis model comparing the three treatment 
alternatives. The model captures: rates, frequency, duration of hospitalization, stable 
days(duration of out-patient follow-up) that health care resource utilization and 
associated costs. Primary outcomes were: the proportion of patient re-hospitalization; 
the frequency of hospitalization per patient; the number of hospitalization days per 
patient; the number of stable days and total direct and indirect cost per patient per 
years. Costs are in year 2007 Korea Wons. RESULTS: Based on model projections, 
the proportions of patients experiencing re-hospitalization after 1 year treatment were 
19.0% for risperidone LAI, 25.0% oral olanzapine and 26.6% for oral risperidone, 
respectively. The mean number of days of re-hospitalization per patient per year was 
16.6 for risperidone LAI, 21.9 oral olanzapine and 23.1 for oral risperidone, respec-
tively. This would translate into total cost savings with risperidone LAI compared 
with oral olanzapine of 46,011, while oral risperidone more spend 78,905 respectively. 
The result of sensitivity analyses, patients re-hospitalization rate during 6-month 
treatment were total cost savings with risperidone LAI compared with oral risperidone 
and oral olanzapine. When drug cost of risperidone LAI, reducing 30% and 75%, 
compared with oral risperidone and oral olanzapine are cost-effective medicine. CON-
CLUSIONS: The use of risperidone LAI for treatment of outpatient with schizophrenia 
is predicted in this model to result in better clinical outcomes but higher total health 
care costs over 1 year than its comparators, oral risperidone and oral olanzapine. 
Risperidone LAI may therefore be carefully therapeutic option for outpatients with 
schizophrenia in the republic of Korea health care setting.
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OBJECTIVES: To assess the cost-effectiveness of olanzapine long-acting injection 
(OLAI) compared with risperidone long-acting injection (RLAI) for patients with 
schizophrenia in Norway. METHODS: A discrete event simulation (DES) model was 
developed from a Norwegian health care system perspective to estimate the costs and 
outcomes associated with OLAI vs. RLAI for patients with schizophrenia over a ﬁve 
year period. The model focuses on patients that have been non-adherent to oral medi-
cation resulting in recurrent relapses. These patients responded to oral treatment during 
the stablisation phase of their illness and have been modeled as entering the mainte-
nance phase of treatment. DES was considered an appropriate approach due to the 
heterogeneous nature of schizophrenia. Norwegian unit cost and resource utilisation 
data were used. Key clinical inputs were relapse rates and treatment discontinuation 
rates obtained from open-label studies. Occurrences of side-effects, such as post- 
injection syndrome, were accounted for. Cost and outcomes included direct medical 
costs and quality-adjusted life years (QALYs) discounted at a rate of 4%. A range of 
deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Results 
were analysed over a 5-year time horizon. OLAI was found to be dominant over RLAI. 
Incremental costs and outcomes were 63,323 NOK (a7,085) and 0.07 QALYs. 
OLAI was associated with fewer relapses (1.41 vs. 1.81 for RLAI) and a longer time 
on treatment (3.98 years vs. 3.69 years for RLAI). Base case results were most sensitive 
to changes in the relapse and treatment discontinuation rates, the cost of relapse, and 
the time horizon. Probabilistic results conﬁrmed OLAI’s dominance over RLAI. CON-
CLUSIONS: The economic evaluation indicates that OLAI is highly cost-effective 
compared to RLAI. As an efﬁcacious and well-tolerated treatment, OLAI constitutes 
an important maintenance treatment option for patients with schizophrenia experienc-
ing recurrent relapse and previously struggling with adherence to oral medication.
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OBJECTIVES: Compliance with pharmacologic treatment in schizophrenia is directly 
associated with the successful control of the condition. The objective of this study is 
to estimate the cost-effectiveness of quetiapine XR in the treatment of schizophrenia 
compared to paliperidone (ER) and quetiapine IR. METHODS: Model: A Markov 
model, with three disease states (mild, moderate and severe) was constructed with a 
time horizon of 1-year, based on Edwards 2005. The analysis was performed from 
the Turkish health care payer perspective. Patient group: Adult patients with schizo-
phrenia receiving treatment. Data sources: Clinical data were acquired from local and 
international literature. Resource use data were provided by an expert panel. Prices 
of medications and other costs related to treatment of schizophrenia were obtained 
from the Ministry of Health Drug Price List in November 2008, and the Price Lists 
of Social Security Institution in 2008, respectively. Outcomes: Clinical outcome 
was deﬁned as the number of relapses and hospitalizations within one year period. 
Economic outcome was the calculated annual cost of disease. Only direct medical 
costs, i.e. treatment, laboratory examinations and health care, were considered. 
RESULTS: Total annual cost of disease is a1.450 for quetiapine XR, lower as com-
pared to quetiapine IR (a1.653), quetiapine IR pool (a1,606) and paliperidone 
(a1.898). Annual hospitalizations rate is 1149 for quetiapine XR and paliperidone, 
and 1174 for quetiapine IR. Annual relapse rate is 2569 for quetiapine XR and pali-
peridone, and 2623 for quetiapine IR. Quetiapine XR, with its lower cost, is superior 
to paliperidone on cost-minimization manner. Quetiapine XR has dominated quetiap-
ine IR on cost-effectiveness manner. Sensitivity analyses prove that results are quite 
